🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareSemaglutide and addictive behavior reduction — need advice Page 3

Semaglutide and addictive behavior reduction — need advice

Dr.RenalNash Fri, Sep 19, 2025 at 1:34 AM 30 replies 1,683 viewsPage 3 of 6
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Sep 20, 2025 at 10:28 AM#11
Dr.AddMedPHL said:
If two explanations both fit, the useful question is which one predicts something the other does not.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

10 10emily_PDX, Dr.SleepRoch, laura_annarbor and 7 others
Reply Quote Save Share Report
SkepticalSean
Member
98
345
Jan 2025
Maine
Sep 20, 2025 at 1:35 PM#12
alex_tucson said:
Steady state is the thing most people miss.

Genuinely useful, thank you. I had the facts and not the framework.

9 9paige_pharma, emma_london, tammy_FL and 6 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Sep 20, 2025 at 4:42 PM#13
Dr.AddMedPHL said:
If two explanations both fit, the useful question is which one predicts something the other does not.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Last edited: Sep 20, 2025 at 6:42 PM
8 8HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 5 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Sep 20, 2025 at 7:49 PM#14

The figures, for anyone assembling their own picture. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

Happy to go further on any of that.

7 7Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 4 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Sep 20, 2025 at 10:56 PM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Report rather than reply if it drifts again.

6 6PurityPaulOR, MaxMetOK, MounjBrad and 3 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register